English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Medicine Healthcare & Pharm
Innovative Vaccine Engine Continues to Drive Growth: CanSinoBIO Enters a New Growth Cycle
Aug 20, 2025 20:30 HKT
創新疫苗引擎持續驅動 康希諾開啟新增長週期
Aug 20, 2025 20:22 HKT
创新疫苗引擎持续驱动 康希诺开启新增长周期
Aug 20, 2025 20:02 HKT
Australian Breakthrough by Cholrem: Cyclodextrin Therapy Reverses Heart Disease, Hailed as Greatest Advance Since Statins
Aug 19, 2025 21:00 HKT
CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers
Aug 19, 2025 15:00 HKT
康哲药业(867.HK,8A8.SG)上半年营收净利双升 战略转型跑出增长新动能
Aug 19, 2025 11:53 HKT
康哲藥業(867.HK,8A8.SG)上半年營收淨利雙升 戰略轉型跑出增長新動能
Aug 19, 2025 11:53 HKT
Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC
Aug 15, 2025 20:15 HKT
艾曲莫德入選《2025 ACG臨床指南:成人潰瘍性結腸炎》,獲強烈推薦用於中重度潰瘍性結腸炎的誘導緩解及維持緩解治療
Aug 15, 2025 20:07 HKT
艾曲莫德入选《2025 ACG临床指南:成人溃疡性结肠炎》,获强烈推荐用于中重度溃疡性结肠炎的诱导缓解及维持缓解治疗
Aug 15, 2025 19:56 HKT
OrbusNeich Records Growth in 2025 Interim Results, Revenue and Net Profit Reach US$83.6 Million and US$19.8 Million Respectively
Aug 15, 2025 19:11 HKT
業聚醫療2025年中期業績收入及純利雙雙增長 分別達8,360萬美元及1,980萬美元
Aug 15, 2025 18:53 HKT
业聚医疗2025年中期业绩收入及纯利双双增长 分别达8,360万美元及1,980万美元
Aug 15, 2025 18:10 HKT
Everest Medicines' New Drug Application for Etrasimod Accepted in Taiwan, Marking Another Milestone in Asia Market Access
Aug 14, 2025 18:00 HKT
雲頂新耀維長寧(艾曲莫德)在中國台灣新藥上市申請獲受理 亞洲市場准入再迎里程碑
Aug 14, 2025 17:12 HKT
云顶新耀维长宁(艾曲莫德)在中国台湾新药上市申请获受理 亚洲市场准入再迎里程碑
Aug 14, 2025 17:12 HKT
NMPA已受理亿胜生物关于EB12-20145P(HLX04-O)用于治疗湿性年龄相关性黄斑变性的生物制品许可申请
Aug 13, 2025 21:25 HKT
NMPA Accepted Essex's Biologics License Application for EB12-20145P (HLX04-O) for the Treatment of Wet Age-Related Macular Degeneration
Aug 13, 2025 20:24 HKT
NMPA已受理億勝生物關於EB12-20145P(HLX04-O)用於治療濕性年齡相關性黃斑變性的生物製品許可申請
Aug 13, 2025 20:24 HKT
AsiaMedic Reports 26% Revenue Growth to S$16.6 million in 1H2025, Led by Strong Diagnostic Imaging Performance
Aug 13, 2025 14:00 HKT
<< Previous  Next >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: